Mon. May 25th, 2026
Spread the love

 

US President Donald Trump filed a $15 billion defamation lawsuit against the New York Times on Monday, accusing the outlet of a “decades-long pattern” of smears driven by feelings of “actual malice.”

Trump, 79, has intensified his long-established hostility toward the media since his return to the White House, repeatedly badmouthing journalists critical of his administration, restricting access and bringing lawsuits.

The Times reported last week that Trump had threatened legal action against it in relation to its articles on a lewd birthday note allegedly given to sex offender Jeffrey Epstein. The Republican president has denied authoring the note.

READ ALSO: As King Charles Hosts Trump, What Do UK State Visits Entail?

(FILES) US President Donald Trump speaks during a news conference in the Brady Briefing Room of the White House on June 27, 2025, in Washington, DC. (Photo by ANDREW CABALLERO-REYNOLDS / AFP)

 

“The New York Times has been allowed to freely lie, smear, and defame me for far too long, and that stops, NOW!” he wrote on his Truth Social platform.

The lawsuit also named four New York Times reporters and the publisher Penguin Random House as defendants, according to an 85-page complaint filed in the US District Court for Florida’s Middle District.

The document cited three articles that came out between September and October last year, and a book by reporters Russ Buettner and Susanne Craig also published around that time.

“The Book and Articles are part of a decades-long pattern by the New York Times of intentional and malicious defamation against President Trump,” read the complaint, which was dated Monday.

“The Times has become a leading, and unapologetic, purveyor of falsehoods against President Trump on the legacy media landscape.”

(FILES) The New York times headquarters building is seen in New York City on December 17, 2024. (Photo by CHARLY TRIBALLEAU / AFP)

 

The New York Times did not immediately return AFP’s request for comment.

Trump’s lawsuit alleged that the Times deviated from its typical journalistic patterns and industry best practices when covering him, such as writing articles “in the most antagonistic and negative way” and not giving him sufficient time to respond before publishing.

“Put bluntly, Defendants baselessly hate President Trump in a deranged way,” the complaint read.

The court was asked to grant compensatory damages of not less than $15 billion and additional punitive damages “in an amount to be determined upon trial.”

In July, Trump sued media magnate Rupert Murdoch and The Wall Street Journal for at least $10 billion after it reported on the existence of a book and a letter he allegedly sent to Epstein.

Paramount settled Trump’s lawsuit over election coverage on CBS News’ flagship show “60 Minutes” for $16 million the same month. He had alleged that the program deceptively edited an interview with his 2024 election rival, Kamala Harris, in her favor.

The post Trump Files $15bn Lawsuit Against New York Times appeared first on Channels Television.

By admin

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.